Kolon TissueGene starts Phase III clinical trial for ‘Invossa’
Kolon TissueGene(CEO Bum-Seop Lee & Woo-Seok Lee) announced on the 6th that they acquired the Chemistry, Manufacturing and Controls(CMC) from the U.S. FDA and would start a Phase III clinical trial in the U.S.
Kolon TissueGene acquired approval of the Phase III clinical trial on May 2015 and has...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
